echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > eClinicalMedicine: The team of Prof. Zixiao Li/Yongjun Wang proposed an accurate phenotype of ischemic stroke

    eClinicalMedicine: The team of Prof. Zixiao Li/Yongjun Wang proposed an accurate phenotype of ischemic stroke

    • Last Update: 2022-10-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In September 2022, the team of Professors Li Zixiao and Wang Yongjun of the Neurology Center of Beijing Tiantan Hospital affiliated to Capital Medical University published a report entitled "Data-driven clustering approach to identify novel phenotypes using multiple biomarkers in acute ischaemic" in the international journal eClinicalMedicine stroke: a retrospective, multicentre cohort study" research paper


    Based on the big data-driven first comprehensive and systematic analysis of patients with acute ischemic stroke, this study proposes a new biomarker-based precise phenotype of acute ischemic stroke, realizes accurate risk stratification of stroke population, reveals the pathophysiology mechanism related to AIS poor prognosis, and lays a foundation


    Acute ischemic stroke (AIS) is a major disease that seriously threatens human health and life, and has become one of the leading causes of


    In order to answer the above important clinical questions, the team of Prof Li Zixiao and Prof.


    This study applies machine learning methods to find reliable biomarkers in the national stroke cohort, and for the first time exploratorically constructs an accurate phenotype of acute ischemic stroke using biomarkers, which is conducive to further understanding the pathophysiology mechanism of the occurrence and development of ischemic stroke and providing direction


    Fig.


    The research was funded by the Key Research Project of Beijing Natural Science Foundation (Z200016), the Special Project of Pharmaceutical Collaborative Science and Technology Innovation of Beijing Municipal Science and Technology Commission (Z201100005620010), the National Natural Science Foundation of China (82101360, 92046016, 82171270), the Medical and Health Science and Technology Innovation Engineering Project of the Chinese Academy of Medical Sciences (2019-I2M-5-029) and the Stroke Precision Clinical Diagnosis and Treatment and Research Center of Capital Medical University


    Wang Yongjun

    Professor of Neurology, Chief Physician, Doctoral Supervisor, President of Beijing Tiantan Hospital affiliated to Capital Medical University, Director of the National Medical Quality Control Center for Neurological Diseases, Deputy Director of the National Clinical Research Center for Neurological Diseases, Director of the Beijing Brain Protection High-Precision Innovation Center, Chairman of the Neurology Branch of the Chinese Medical Association, and Editor-in-Chief


    Li Zixiao

    Professor of Neurology, Chief Physician, Doctoral Supervisor, Deputy Director


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.